Victoria Huiyu Chen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circumcision, Female | 2 | 2022 | 31 | 0.990 |
Why?
|
| Jaundice, Obstructive | 1 | 2023 | 20 | 0.930 |
Why?
|
| Duodenal Diseases | 1 | 2023 | 102 | 0.880 |
Why?
|
| Diverticulum | 1 | 2023 | 134 | 0.850 |
Why?
|
| Cholestasis | 1 | 2023 | 378 | 0.740 |
Why?
|
| Sex Offenses | 1 | 2022 | 354 | 0.610 |
Why?
|
| New York City | 2 | 2023 | 705 | 0.230 |
Why?
|
| Enterovirus B, Human | 1 | 2019 | 52 | 0.170 |
Why?
|
| Coxsackievirus Infections | 1 | 2019 | 44 | 0.170 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2019 | 165 | 0.160 |
Why?
|
| Cysteine Endopeptidases | 1 | 2019 | 563 | 0.140 |
Why?
|
| Sexual Behavior | 1 | 2023 | 2049 | 0.110 |
Why?
|
| Refugees | 1 | 2020 | 511 | 0.110 |
Why?
|
| Leadership | 1 | 2022 | 1357 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2011 | 1874 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2019 | 1899 | 0.100 |
Why?
|
| Myocarditis | 1 | 2019 | 768 | 0.100 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 3839 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2023 | 40545 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 1479 | 0.090 |
Why?
|
| Streptococcus agalactiae | 1 | 2011 | 375 | 0.090 |
Why?
|
| Radial Artery | 1 | 2011 | 193 | 0.090 |
Why?
|
| Health Personnel | 1 | 2022 | 3217 | 0.080 |
Why?
|
| Liver | 1 | 2023 | 7479 | 0.080 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2011 | 349 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 3020 | 0.070 |
Why?
|
| Endocarditis, Bacterial | 1 | 2011 | 455 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 850 | 0.070 |
Why?
|
| Streptococcal Infections | 1 | 2011 | 636 | 0.070 |
Why?
|
| Femoral Artery | 1 | 2011 | 845 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 482 | 0.070 |
Why?
|
| Myocardium | 1 | 2019 | 4775 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77410 | 0.070 |
Why?
|
| HIV Infections | 2 | 2022 | 16715 | 0.060 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 641 | 0.060 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 7658 | 0.060 |
Why?
|
| Child | 2 | 2023 | 77637 | 0.060 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 1073 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4569 | 0.060 |
Why?
|
| Counseling | 2 | 2022 | 1523 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 2159 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2011 | 1205 | 0.050 |
Why?
|
| Hemorrhage | 2 | 2011 | 3458 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 29140 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 56392 | 0.050 |
Why?
|
| Pyridines | 1 | 2012 | 2827 | 0.050 |
Why?
|
| Humans | 12 | 2023 | 743811 | 0.050 |
Why?
|
| Female | 7 | 2023 | 380020 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2011 | 4576 | 0.040 |
Why?
|
| Neuregulin-1 | 1 | 2019 | 142 | 0.040 |
Why?
|
| Thrombosis | 1 | 2012 | 2968 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 795 | 0.040 |
Why?
|
| Confidentiality | 1 | 2021 | 613 | 0.040 |
Why?
|
| Peptides | 1 | 2008 | 4406 | 0.030 |
Why?
|
| South Africa | 1 | 2021 | 1731 | 0.030 |
Why?
|
| Presenilin-1 | 1 | 2019 | 635 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 3070 | 0.030 |
Why?
|
| Perception | 1 | 2020 | 1198 | 0.030 |
Why?
|
| Adolescent | 1 | 2022 | 85729 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6363 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2022 | 2483 | 0.030 |
Why?
|
| Protein Transport | 1 | 2019 | 1988 | 0.030 |
Why?
|
| Adult | 3 | 2022 | 213889 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 3130 | 0.030 |
Why?
|
| Male | 5 | 2023 | 349776 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 9272 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2012 | 169 | 0.020 |
Why?
|
| New Zealand | 1 | 2011 | 355 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 25032 | 0.020 |
Why?
|
| Punctures | 1 | 2011 | 374 | 0.020 |
Why?
|
| Learning Curve | 1 | 2011 | 208 | 0.020 |
Why?
|
| Middle Aged | 2 | 2022 | 213241 | 0.020 |
Why?
|
| Curriculum | 1 | 2022 | 3603 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 935 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 3921 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2617 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7793 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 1422 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5251 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2012 | 1489 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 2274 | 0.010 |
Why?
|
| Models, Biological | 1 | 2019 | 9582 | 0.010 |
Why?
|
| Aortic Valve | 1 | 2012 | 1920 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2011 | 5078 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2011 | 1537 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18027 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2011 | 23327 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2008 | 1161 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2011 | 9848 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 2150 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2707 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2011 | 4687 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2008 | 2789 | 0.010 |
Why?
|
| Aged | 3 | 2012 | 163178 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 6311 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 3207 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2011 | 63042 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 81154 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39001 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 40038 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 168660 | 0.000 |
Why?
|
| Risk Factors | 1 | 2011 | 72252 | 0.000 |
Why?
|